Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs for autoimmune diseases, headed by a Graves' disease candidate. The Cambridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback